Molecular prognostic markers in locally advanced colon cancer

Clinical Colorectal Cancer

Volumn 6, Issue 10, 2007, Pages 683-690

  Lurje, Georg ^a   Zhang, Wu ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

DNA ploidy; Microsatellite instability; Mismatch repair genes; Transforming growth factor

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MOLECULAR MARKER; OXALIPLATIN; THYMIDYLATE SYNTHASE;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE REGULATION; CELL GROWTH; CHROMOSOME 17P; CHROMOSOME 18Q; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DNA SEQUENCE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HUMAN; LIFE EXPECTANCY; META ANALYSIS; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; OUTCOME ASSESSMENT; PLOIDY; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 36849088076     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2007.n.037     Document Type: Review

References (125)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24:4085-91.
3. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122:321-26.
4. Shulman K, Schilsky RL. Adjuvant therapy of colon cancer. Semin Oncol 1995; 22:600-10.
5. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344:1196-206.
6. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-51.
7. Bendardaf R, Lamlum H, Pyrhonen S. Prognostic and predictive molecular markers in colorectal carcinoma. Anticancer Res 2004; 24:2519-30.
8. Gatta G, Faivre J, Capocaccia R, et al. Survival of colorectal cancer patients in Europe during the period 1978-1989. Eur J Cancer 1998; 34:2176-83.
9. Burdy G, Panis Y, Alves A, et al. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001; 44:1682-88.
10. Caplin S, Cerottini JP, Bosman FT, et al. For patients with Dukes' B (TNM stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. Cancer 1998; 83:666-72.
11. Compton CC. Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol 2003; 16:376-88.
12. Kanemitsu Y, Kato T, Hirai T, et al. Survival after curative resection for mucinous adenocarcinoma of the colorectum. Dis Colon Rectum 2003; 46:160-67.
13. Merkel S, Wein A, Gunther K, et al. High-risk groups of patients with stage II colon carcinoma. Cancer 2001; 92:1435-43.
14. Newland RC, Dent OF, Chapuis PH, et al. Survival after curative resection of lymph node negative colorectal carcinoma. A prospective study of 910 patients. Cancer 1995; 76:564-71.
15. Psathakis D, Schiedeck TH, Krug F, et al. Ordinary colorectal adenocarcinoma vs. primary colorectal signet-ring cell carcinoma: study matched for age, gender, grade, and stage. Dis Colon Rectum 1999; 42:1618-25.
16. Kuebler JP, Wieand HS, O'Connell, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25:2198-204.
17. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22:3408-19.
18. Fluorouracil, leucovorin, and oxaliplatin with or without bevacizumab in treating patients who have undergone surgery for stage II or stage III colon cancer. ClinicalTrials.gov Web site. Available at: http://www.clinicaltrials. gov/ct/show/NCT00096278. Accessed: July 19, 2007.
19. Comparison of combination chemotherapy regimens with or without cetuximab in treating patients who have undergone surgery for stage III colon cancer. ClinicalTrials.gov Web site. Available at: http://clinicaltrials.gov/ct/show/ NCT00079274. Accessed: July 19, 2007.
20. Pretlow TP, Barrow BJ, Ashton WS, et al. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 1991; 51:1564-67.
21. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67.
22. Fearon ER. Genetic alterations underlying colorectal tumorigenesis. Cancer Surv 1992; 12:119-36.
23. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525-32.
24. Fujiwara T, Stolker JM, Watanabe T, et al. Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am J Pathol 1998; 153:1063-78.
25. Kennedy EP, Hamilton SR. Genetics of colorectal cancer. Semin Surg Oncol 1998; 15:126-30.
26. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260:816-19.
27. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260:812-16.
28. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998; 338:1481-87.
29. Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363:558-61.
30. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342:69-77.
31. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159-70.
32. Sinicrope FA, Rego RL, Halling KC, et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 2006; 131:729-37.
33. Duesberg P, Rausch C, Rasnick D, et al. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci U S A 1998; 95:13692-7.
34. Halling KC, French AJ, McDonnell SK, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999; 91:1295-1303.
35. Grady WM, Willis JE, Trobridge P, et al. Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations. Int J Cancer 2006; 118:600-08.
36. Hoosein NM, McKnight MK, Levine AE, et al. Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-beta 1. Exp Cell Res 1989; 181:442-53.
37. Manning AM, Williams AC, Game SM, et al. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor beta (TGF-beta): conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-beta. Oncogene 1991; 6:1471-6.
38. Markowitz SD, Myeroff L, Cooper MJ, et al. A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progresses to tumorigenicity and transforming growth factor-beta independence without inactivating the p53 tumor suppressor gene. J Clin Invest 1994; 93:1005-13.
39. Markowitz S, Hines JD, Lutterbaugh J, et al. Mutant K-ras oncogenes in colon cancers do not predict patient's chemotherapy response or survival. Clin Cancer Res 1995; 1:441-5.
40. Parsons R, Myeroff LL, Liu B, et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 1995; 55:5548-50.
41. Macias-Silva M, Abdollah S, Hoodless PA, et al. MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996; 87:1215-24.
42. Riggins GJ, Kinzler KW, Vogelstein B, et al. Frequency of Smad gene mutations in human cancers. Cancer Res 1997; 57:2578-80.
43. Riggins GJ, Thiagalingam S, Rozenblum E, et al. Mad-related genes in the human. Nat Genet 1996; 13:347-9.
44. Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999; 117:123-31.
45. Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007; 25:767-72.
46. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23:609-18.
47. Lanza G, Matteuzzi M, Gafa R, et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998; 79:390-5.
48. Burke D, Gasdaska P, Hartwell L. Dominant effects of tubulin overexpression in Saccharomyces cerevisiae. Mol Cell Biol 1989; 9:1049-59.
49. Futcher B, Carbon J. Toxic effects of excess cloned centromeres. Mol Cell Biol 1986; 6:2213-22.
50. Mayer VW, Aguilera A. High levels of chromosome instability in polyploids of Saccharomyces cerevisiae. Mutat Res 1990; 231:177-86.
51. Holliday R. Chromosome error propagation and cancer. Trends Genet 1989; 5:42-5.
52. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386:623-7.
53. Lengauer C, Kinzler KW, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci U S A 1997; 94:2545-50.
54. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396:643-9.
55. Bast RC, Jr, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1865-78.
56. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244:217-21.
57. Fearon ER, Cho KR, Nigro JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990; 247:49-56.
58. Kern SE, Fearon ER, Tersmette KW, et al. Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]. JAMA 1989; 261:3099-103.
59. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358:15-6.
60. Livingstone LR, White A, Sprouse J, et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70:923-35.
61. Yin Y, Tainsky MA, Bischoff FZ, et al. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70:937-48.
62. Lin JK, Chang SC, Yang YC, et al. Loss of heterozygosity and DNA aneuploidy in colorectal adenocarcinoma. Ann Surg Oncol 2003; 10:1086-94.
63. Carroll PE, Okuda M, Horn HF, et al. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 1999; 18:1935-44.
64. Weber RG, Bridger JM, Benner A, et al. Centrosome amplification as a possible mechanism for numerical chromosome aberrations in cerebral primitive neuroectodermal tumors with TP53 mutations. Cytogenet Cell Genet 1998; 83:266-9.
65. Herskowitz I. Functional inactivation of genes by dominant negative mutations. Nature 1987; 329:219-22.
66. Kraiss S, Quaiser A, Oren M, et al. Oligomerization of oncoprotein p53. J Virol 1988; 62:4737-44.
67. North S, Hainaut P. p53 and cell-cycle control: a finger in every pie. Pathol Biol (Paris) 2000; 48:255-70.
68. Pirollo KF, Bouker KB, Chang EH. Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 2000; 11:419-32.
69. Smith DM, Gao G, Zhang X, et al. Regulation of tumor cell apoptotic sensitivity during the cell cycle (review). Int J Mol Med 2000; 6:503-7.
70. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci 2000; 910:121-137; discussion 137-9.
71. Ahnen DJ, Feigl P, Quan G, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998; 58:1149-58.
72. Fearon ER. DCC: is there a connection between tumorigenesis and cell guidance molecules? Biochim Biophys Acta 1996; 1288:M17-23.
73. Keino-Masu K, Masu M, Hinck L, et al. Deleted in colorectal cancer (DCC) encodes a netrin receptor. Cell 1996; 87:175-85.
74. Alazzouzi H, Alhopuro P, Salovaara R, et al. SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 2005; 11:2606-11.
75. Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev 2004; 23:11-27.
76. Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005; 41:2060-70.
77. Oxaliplatin, leucovorin, and fluorouracil with or without bevacizumab in treating patients who have undergone surgery for stage II colon cancer; Eastern Cooperative Oncology Group 5202. ClinicalTrials.gov Web site. Available at: http://clinicaltrials.gov/ct/show/NCT00217737. Accessed: July 19, 2007.
78. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85:692-6.
79. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998; 90:675-84.
80. Chiang JM, Chou YH, Chou TB. K-ras codon 12 mutation determines the polypoid growth of colorectral cancer. Cancer Res 1998; 58:3289-93.
81. Yamagata S, Muto T, Uchida Y, et al. Polypoid growth and K-ras codon 12 mutation in colorectal cancer. Cancer 1995; 75:953-7.
82. Elnatan J, Goh HS, Smith DR. C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Eur J Cancer 1996; 32A:491-7.
83. Moerkerk P, Arends JW, van Driel M, et al. Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res 1994; 54:3376-8.
84. Oudejans JJ, Slebos RJ, Zoetmulder FA, et al. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer 1991; 49:875-9.
85. Suchy B, Zietz C, Rabes HM. K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis. Int J Cancer 1992; 52:30-3.
86. Andreyev HJ, Tilsed JV, Cunningham D, et al. K-ras mutations in patients with early colorectal cancers. Gut 1997; 41:323-9.
87. Kato M, Ito Y, Kobayashi S, et al. Detection of DCC and Ki-ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence. Cancer 1996; 77:1729-35.
88. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4:988-93.
89. Jass JR. Serrated adenoma of the colorectum and the DNA-methylator phenotype. Nat Clin Pract Oncol 2005; 2:398-405.
90. Laird PW. Cancer epigenetics. Hum Mol Genet 2005; 14 Spec No 1:R65-76.
91. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-28.
92. Hawkins N, Norrie M, Cheong K, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 2002; 122:1376-87.
93. Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005; 129:837-45.
94. van Rijnsoever M, Grieu F, Elsaleh H, et al. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 2002; 51:797-802.
95. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38:787-93.
96. Whitehall VL, Wynter CV, Walsh MD, et al. Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res 2002; 62:6011-4.
97. Matsuzaki K, Deng G, Tanaka H, et al. The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin Cancer Res 2005; 11:8564-9.
98. Goel A, Nagasaka T, Arnold CN, et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 2007; 132:127-38.
99. Wallner M, Herbst A, Behrens A, et al. Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res 2006; 12:7347-52.
100. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3:253-66.
101. Jen J, Wu L, Sidransky D. An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Ann N Y Acad Sci 2000; 906:8-12.
102. Fiegl H, Millinger S, Mueller-Holzner E, et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005; 65:1141-5.
103. Koyanagi K, Mori T, O'Day SJ, et al. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res 2006; 66:6111-7.
104. Lecomte T, Berger A, Zinzindohoue F, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 2002; 100:542-8.
105. Leung WK, To KF, Chu ES, et al. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer 2005; 92:2190-4.
106. Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002; 62:371-5.
107. Widschwendter A, Muller HM, Fiegl H, et al. DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res 2004; 10:565-71.
108. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179:663-6.
109. Danenberg PV. Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta 1977; 473:73-92.
110. Danenberg PV. Pharmacogenomics of thymidylate synthase in cancer treatment. Front Biosci 2004; 9:2484-94.
111. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1:65-70.
112. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22:529-36.
113. Hitre E, Budai B, Adleff V, et al. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet Genomics 2005; 15:723-30.
114. Dotor E, Cuatrecases M, Martinez-Iniesta M, et al. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 2006; 24:1603-11.
115. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004; 22:1564-71.
116. Arango D, Laiho P, Kokko A, et al. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology 2005; 129:874-84.
117. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.
118. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6.
119. Folkman J. Seminars in medicine of the Beth Israel Hospital. Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333:1757-63.
120. Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265:1582-4.
121. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006; 5:1779-87.
122. Giantonio BJ, Levy DE, O'Dwyer PJ, et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Ann Oncol 2006; 17:1399-403.
123. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
124. Lurje G, Schultheis AM, Hendifar AE, et al. VEGF and VEGF receptor-2 (VEGFR2) gene polymorphisms predict tumor recurrence in stage II and III colon cancer. J Clin Oncol 2007; 25(18 suppl):164s (Abstract 4004).
125. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24:5313-27.